Table 3.
Univariate and multivariate analysis of OS.
| Variable | Parameter | Median OS (95% CI) | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|---|---|
| HR (95% CI) | p value | HR (95% CI) | p value | |||
| Overall | – | 31.3 (32.6–49.6) | – | – | – | – |
| Age | ≤ 60 | 28.0 (23.5–40.9) | 1.00 | 0.573 | ||
| >60 | 41.1 (34.2–59.6) | 1.861 (0.214–16.143) | ||||
| Site of the primary tumor in the testicle | Left | 25.6 (19.7–50.5) | 1.00 | – | ||
| Right | 41.1 (34.1–56.9) | – | ||||
| Bilateral | – | – | ||||
| Ann Arbor stage | I–II | 41.1 (32.6–54.2) | 1.00 | 0.507 | ||
| III–IV | 30.3 (23.5–53.5) | 1.607 (0.396–6.518) | ||||
| B symptoms | Present | 28.7 (15.1–45.4) | 1.00 | – | ||
| Absent | 32.4 (33.2–52.6) | – | ||||
| Extranodal involvement (excluding testicular) | 0 | 30.2 (28.5–49.0) | 1.00 | 0.780 | ||
| 1 | 36.2 (25.3–55.6) | 1.794 (0.191–16.865) | ||||
| >1 | 39.2 (−9.8–113.6) | 2.366 (0.14–26.172) | ||||
| IPI score | 0–1 | 45.6 (33.6–64.5) | 1.00 | 0.034 | ||
| 2–5 | 30.8 (26.3–40.1) | 10.597 (1.199–93.621) | ||||
| ECOG performance status | 0 | 31.8 (32.3–57.6) | 1.00 | 0.016 | 1.00 | 0.026 |
| 1 | 31.3 (26.1–42.3) | 14.838 (1.658–132.817) | 20.013 (1.431–279.876) | |||
| Chemotherapy regimen | R-CHOP | 31.4 (33.2–52.6) | 1.00 | 0.901 | ||
| CHOP-like | 23.1 (9.4–56.3) | 1.146 (0.135–9.709) | ||||
| Radiotherapy | Yes | 54.8 (32.2–81.9) | 1.00 | 0.700 | ||
| No | 29.6 (28.1–41.4) | 1.365 (020–6.649) | ||||
| Prophylactic intrathecal injection | Yes | 28.9 (28.6–53.6) | 1.00 | 0.171 | ||
| No | 33.3 (28.5–53.8) | 2.400 (0.645–11.937) | ||||
| LDH | ≤ 220 | 43.2 (36.9–61.1) | 1.00 | 0.461 | ||
| >220 | 26.0 (21.1–36.8) | 1.909 (0.342–10.665) | ||||
| Neutrophil counts | ≤ 3.03 | 31.2 (23.5–58.3) | 1.00 | 0.200 | ||
| >3.03 | 31.4 (31.1–51.4) | 3.973 (0.482–32.735) | ||||
| Lymphocyte counts | ≤ 1.12 | 44.6 (30.3–71.5) | 1.00 | 0.110 | ||
| >1.12 | 28.5 (28.6–48.3) | 0.305 (0.071–1.308) | ||||
| Monocyte counts | ≤ 0.55 | 41.1 (36.3–57.0) | 1.00 | 0.549 | ||
| >0.55 | 23.1 (21.2–28.0) | 1239.773 (0.000–1.601E+13) | ||||
| Platelet counts | ≤ 209.00 | 31.3 (30.2–50.0) | 1.00 | 0.308 | ||
| >209.00 | 44.5 (22.0–67.6) | 0.027 (0.000–27.619) | ||||
| NLR | ≤ 2.66 | 32.3 (30.3–56.2) | 1.00 | 0.025 | ||
| >2.66 | 30.9 (26.3–50.2) | 11.186 (1.356–92.275) | ||||
| PLR | ≤ 59.18 | Constant | 1.00 | 1.000 | ||
| >59.18 | 31.4 (33.2–50.5) | 1.00 (0.000–32153.454) | ||||
| LMR | ≤ 3.31 | 26.6 (23.1–36.1) | 1.00 | 0.010 | 1.00 | 0.028 |
| >3.31 | 51.5 (38.7–66.6) | 0.106 (0.019–0.584) | 0.077 (0.008–0.760) | |||
| SII | ≤ 428.40 | 31.3 (27.0–54.4) | 1.00 | 0.106 | ||
| >428.40 | 34.4 (29.6–53.5) | 5.693 (0.692–46.812) | ||||
IPI, International Prognostic Index; ECOG performance status, Eastern Cooperative Oncology Group performance status; CHOP, cyclophosphamide, doxorubicin, vincristine and prednisone; R-CHOP, CHOP plus rituximab; LDH, lactic dehydrogenase; NLR, neutrophil/lymphocyte ratio; PLR, platelet/lymphocyte ratio; LMR, lymphocyte/monocyte ratio; SII, systemic immune-inflammation index. The bold values indicate that p <0.05 and the corresponding factors are significantly associated with survival.